Abcellera Biologics Inc (ABCL) stock news · rev $75.1M
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
This ABCL news page leads with what Abcellera Biologics Inc filed — not a scraped headline mill.
No cached 8-K sentence for ABCL yet. We will not pad this page with generic market recap.
Latest reported ABCL revenue for 2025-12-31 was $75.1M. Net income was -$146.4M. Revenue was up 160.6% from 2024-12-31 to 2025-12-31. ABCL currently screens at market cap $1.12B.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the ABCL stock page; for the tape open the quote page.
ABCL stock news FAQ
What are ABCL's latest revenue and net income?
Latest cached Abcellera Biologics Inc (ABCL) revenue for Dec 31, 2025 was $75.1M. Net income was -$146.4M. Statements: https://lician.com/financials/abcl
How did ABCL revenue change from the prior cached period?
Cached Abcellera Biologics Inc (ABCL) revenue was up 160.6% from $28.8M (Dec 31, 2024) to $75.1M (Dec 31, 2025). Statements: https://lician.com/financials/abcl
What is ABCL's market cap?
Abcellera Biologics Inc (ABCL) market cap is $1.12B on the latest cached fundamentals snapshot.
What kind of company is ABCL?
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
Where is ABCL stock news listed?
Cached stock news for Abcellera Biologics Inc (ABCL) is listed at https://lician.com/news/abcl. Filings: https://lician.com/sec/abcl
Not investment advice.